Pharma chain Rite Aid (RAD), which is in the process of being acquired by Albertsons, has struggled with the deteriorating sales as well as fierce competition from its top rivals like CVS Health (CVS) and Walgreens Boots Alliance (WBA). The downward trend in sales was expected to show up again in the fourth quarter of 2018, mostly due to the transfer of the stores to Walgreens. As anticipated, revenue dropped 8.6% to $5.4 billion during the recent quarter.
The company witnessed contractions in revenues from both segments – the Retail Pharmacy and Pharmacy Services, which fell 10.1% and 4.3% respectively. This fall in the revenue was mainly due to the 1.8% decrease in prescription volume and decline in commercial business.
Off late, Rite Aid has been grabbing the headlines. Firstly, due to its store transfer to Walgreens that was a part of a larger deal. And secondly, due to its takeover by private company Albertsons.
Rite Aid completed the store transfer to Walgreens on March 27, 2018. In relation to this store transfer, during the fourth quarter, the company received an after-tax gain of about $1.2 billion, relating to the 1,554 stores as well as due to the sale of related assets to Walgreens. This led to the drug retailer reporting a net income of $767.1 million, or $0.73 per share, compared to a loss of $21.14 million, or $0.02 per share.
Apart from the sale of 1,554 stores to Walgreens, the company shut down 19 stores during the quarter bringing the total store count to 2,831.
Rite Aid also provided the outlook for 2019 which did not reflect the impact of the pending deal with Albertsons. For the fiscal year 2019, the company expects sales to be in the range of about $21.7 billion to $22.1 billion and net loss is expected to be between $40 million and $95 million.
Rite Aid witnessed contractions in revenues from both segments – the Retail Pharmacy and Pharmacy Services
The awaited merger with the debt-burdened company Albertsons is said to transform the drugstore chain into a food, health and wellness chain. Albertsons selected the stores that Walgreens couldn’t acquire. Once the merger takes place- which is expected to happen later this year – Albertsons plans to go public.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated